CheckMate 025 is a pivotal clinical trial focused on evaluating the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in patients with advanced or metastatic renal cell carcinoma (RCC). This study has significantly influenced the landscape of cancer treatment by offering a new therapeutic option for patients who have previously received anti-angiogenic therapy.
